These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24122770)

  • 1. Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening.
    Pedersen JW; Gentry-Maharaj A; Nøstdal A; Fourkala EO; Dawnay A; Burnell M; Zaikin A; Burchell J; Papadimitriou JT; Clausen H; Jacobs I; Menon U; Wandall HH
    Int J Cancer; 2014 May; 134(9):2180-88. PubMed ID: 24122770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer.
    Burford B; Gentry-Maharaj A; Graham R; Allen D; Pedersen JW; Nudelman AS; Blixt O; Fourkala EO; Bueti D; Dawnay A; Ford J; Desai R; David L; Trinder P; Acres B; Schwientek T; Gammerman A; Reis CA; Silva L; Osório H; Hallett R; Wandall HH; Mandel U; Hollingsworth MA; Jacobs I; Fentiman I; Clausen H; Taylor-Papadimitriou J; Menon U; Burchell JM
    Br J Cancer; 2013 May; 108(10):2045-55. PubMed ID: 23652307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer.
    Pedersen JW; Gentry-Maharaj A; Fourkala EO; Dawnay A; Burnell M; Zaikin A; Pedersen AE; Jacobs I; Menon U; Wandall HH
    Br J Cancer; 2013 Jan; 108(1):107-14. PubMed ID: 23169294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.
    Blixt O; Bueti D; Burford B; Allen D; Julien S; Hollingsworth M; Gammerman A; Fentiman I; Taylor-Papadimitriou J; Burchell JM
    Breast Cancer Res; 2011 Mar; 13(2):R25. PubMed ID: 21385452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes.
    Wandall HH; Blixt O; Tarp MA; Pedersen JW; Bennett EP; Mandel U; Ragupathi G; Livingston PO; Hollingsworth MA; Taylor-Papadimitriou J; Burchell J; Clausen H
    Cancer Res; 2010 Feb; 70(4):1306-13. PubMed ID: 20124478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125).
    Chauhan SC; Singh AP; Ruiz F; Johansson SL; Jain M; Smith LM; Moniaux N; Batra SK
    Mod Pathol; 2006 Oct; 19(10):1386-94. PubMed ID: 16880776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray.
    Pedersen JW; Blixt O; Bennett EP; Tarp MA; Dar I; Mandel U; Poulsen SS; Pedersen AE; Rasmussen S; Jess P; Clausen H; Wandall HH
    Int J Cancer; 2011 Apr; 128(8):1860-71. PubMed ID: 21344374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening.
    Laidi F; Bouziane A; Errachid A; Zaoui F
    Asian Pac J Cancer Prev; 2016; 17(1):335-9. PubMed ID: 26838233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
    Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM
    Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel algorithm to improve specificity in ovarian cancer detection.
    Arjomandi A; Delanoy ML; Walker RP; Binder SR
    Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibody biomarkers for the detection of serous ovarian cancer.
    Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS
    Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.
    Karabudak AA; Hafner J; Shetty V; Chen S; Secord AA; Morse MA; Philip R
    J Cancer Res Clin Oncol; 2013 Oct; 139(10):1757-70. PubMed ID: 23999876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Blood Autoantibodies in the Detection of Colorectal Cancer.
    Negm OH; Hamed MR; Schoen RE; Whelan RL; Steele RJ; Scholefield J; Dilnot EM; Shantha Kumara HM; Robertson JF; Sewell HF
    PLoS One; 2016; 11(7):e0156971. PubMed ID: 27383396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting.
    Chen H; Werner S; Butt J; Zörnig I; Knebel P; Michel A; Eichmüller SB; Jäger D; Waterboer T; Pawlita M; Brenner H
    Oncotarget; 2016 Mar; 7(13):16420-32. PubMed ID: 26909861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
    Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
    Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer.
    Chen H; Werner S; Tao S; Zörnig I; Brenner H
    Cancer Lett; 2014 May; 346(2):178-87. PubMed ID: 24462820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
    Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J
    Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a panel of serum IgG and IgA autoantibodies for early diagnosis of colon cancer.
    Chen M; Lin X; Zhang L; Yu L; Wu Q; Zhang S; Xue F; Huang Y
    Int J Med Sci; 2020; 17(17):2744-2750. PubMed ID: 33162802
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of colorectal cancer.
    Fan CW; Kuo YB; Lin GP; Chen SM; Chang SH; Li BA; Chan EC
    Clin Chim Acta; 2017 Dec; 475():157-163. PubMed ID: 29074220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediagnostic Antibodies to Serum p53 and Subsequent Colorectal Cancer.
    Teras LR; Gapstur SM; Maliniak ML; Jacobs EJ; Gansler T; Michel A; Pawlita M; Waterboer T; Campbell PT
    Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):219-223. PubMed ID: 29254936
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.